OUR TECHnology

Our platform is uniquely able to target multiple misfolded protein aggregates implicated in serious diseases

AN URGENT NEED

Learn about our commitment to address the significant unmet need of patients with neurodegenerative and systemic amyloidosis diseases

LATEST NEWS

Proclara Biosciences Announces Initiation of NPT189 Clinical Development for Systemic Amyloidoses and Provides Pipeline Update